Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion Inhibitor
Open Access
- 15 October 2003
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (8) , 1102-1106
- https://doi.org/10.1086/378302
Abstract
The development of highly active antiretroviral therapy has improved life expectancy and reduced progression to acquired immunodeficiency syndrome in human immunodeficiency virus (HIV)–infected patients. However, resistance to currently available classes of antiretroviral drugs has become a problem, limiting the options for patients with advanced disease who have been heavily treated. Enfuvirtide (T-20; ENF), a synthetic peptide, is the first of a new class of antiretrovirals that block entry of virus into host cells. ENF interferes with conformational changes required for membrane fusion and injection of virus into the host cell. Optimal treatment of HIV infection will likely require combinations of drugs that target novel stages of HIV type 1 entry and replication.Keywords
This publication has 21 references indexed in Scilit:
- Human Immunodeficiency Virus Type 1 Attachment, Coreceptor, and Fusion Inhibitors Are Active against both Direct andtransInfection of Primary CellsJournal of Virology, 2003
- Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kineticsProceedings of the National Academy of Sciences, 2002
- New anti‐HIV agents and targetsMedicinal Research Reviews, 2002
- Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitorAIDS, 2002
- Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patientsAIDS, 2002
- New developments in anti-HIV chemotherapyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2002
- Peptide and Non-peptide HIV Fusion InhibitorsCurrent Pharmaceutical Design, 2002
- Sensitivity of Human Immunodeficiency Virus Type 1 to Fusion Inhibitors Targeted to the gp41 First Heptad Repeat Involves Distinct Regions of gp41 and Is Consistently Modulated by gp120 Interactions with the CoreceptorJournal of Virology, 2001
- Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120Journal of Virology, 2000
- Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.Proceedings of the National Academy of Sciences, 1996